ES2280150T3 - Asociacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, su composicion, proceso de preparacion y uso. - Google Patents
Asociacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, su composicion, proceso de preparacion y uso. Download PDFInfo
- Publication number
- ES2280150T3 ES2280150T3 ES04808700T ES04808700T ES2280150T3 ES 2280150 T3 ES2280150 T3 ES 2280150T3 ES 04808700 T ES04808700 T ES 04808700T ES 04808700 T ES04808700 T ES 04808700T ES 2280150 T3 ES2280150 T3 ES 2280150T3
- Authority
- ES
- Spain
- Prior art keywords
- composition
- treatment
- tinidazole
- fluconazole
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 50
- 229960005053 tinidazole Drugs 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims description 29
- 208000015181 infectious disease Diseases 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title claims description 6
- 238000000034 method Methods 0.000 title description 5
- 230000008569 process Effects 0.000 title description 4
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229960004884 fluconazole Drugs 0.000 claims abstract description 19
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 claims abstract description 19
- 210000004994 reproductive system Anatomy 0.000 claims abstract description 9
- 208000035473 Communicable disease Diseases 0.000 claims abstract description 8
- 206010046914 Vaginal infection Diseases 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 201000008100 Vaginitis Diseases 0.000 claims description 6
- 208000003322 Coinfection Diseases 0.000 claims description 5
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 244000005700 microbiome Species 0.000 claims description 4
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 229960000913 crospovidone Drugs 0.000 claims description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 241000192041 Micrococcus Species 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 241000186046 Actinomyces Species 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 2
- 241000224527 Trichomonas vaginalis Species 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 9
- 239000003826 tablet Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 6
- 208000037009 Vaginitis bacterial Diseases 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 210000001215 vagina Anatomy 0.000 description 6
- 241000224526 Trichomonas Species 0.000 description 5
- 210000003756 cervix mucus Anatomy 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 229960000282 metronidazole Drugs 0.000 description 5
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 5
- 229960004076 secnidazole Drugs 0.000 description 5
- 208000010484 vulvovaginitis Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 241000222122 Candida albicans Species 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000008029 eradication Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010046901 vaginal discharge Diseases 0.000 description 4
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010007134 Candida infections Diseases 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 201000003984 candidiasis Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 3
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 229940083666 fluconazole 150 mg Drugs 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 229940079302 itraconazole 200 mg Drugs 0.000 description 2
- 229960004125 ketoconazole Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 150000004957 nitroimidazoles Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- ZCJYUTQZBAIHBS-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole Chemical compound ClC1=CC(Cl)=CC=C1C(OCC=1C=CC(SC=2C=CC=CC=2)=CC=1)CN1C=NC=C1 ZCJYUTQZBAIHBS-UHFFFAOYSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- 150000004958 5-nitroimidazoles Chemical class 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010058040 Abdominal sepsis Diseases 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 206010061977 Genital infection female Diseases 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 241000203736 Mobiluncus Species 0.000 description 1
- 241000204048 Mycoplasma hominis Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000005448 Trichomonas Infections Diseases 0.000 description 1
- 206010044620 Trichomoniasis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000032159 Vaginal inflammation Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 229940058965 antiprotozoal agent against amoebiasis and other protozoal diseases nitroimidazole derivative Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940005067 clindamycin 300 mg Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 229960001274 fenticonazole Drugs 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940096441 metronidazole 500 mg Drugs 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001374 post-anti-biotic effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 208000002003 vulvitis Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US762616 | 1996-12-09 | ||
| US10/762,616 US8309103B2 (en) | 2004-01-22 | 2004-01-22 | Association of fluconazole-tinidazole for the treatment of vaginal infections, its composition, preparation process and usage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2280150T1 ES2280150T1 (es) | 2007-09-16 |
| ES2280150T3 true ES2280150T3 (es) | 2009-11-18 |
Family
ID=34794897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES04808700T Expired - Lifetime ES2280150T3 (es) | 2004-01-22 | 2004-12-17 | Asociacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, su composicion, proceso de preparacion y uso. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8309103B2 (https=) |
| EP (1) | EP1712229B1 (https=) |
| JP (1) | JP2007518797A (https=) |
| BR (1) | BRPI0418065A (https=) |
| CA (1) | CA2553646C (https=) |
| DE (2) | DE602004021638D1 (https=) |
| ES (1) | ES2280150T3 (https=) |
| WO (1) | WO2005070421A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2008011321A (es) | 2008-09-04 | 2010-03-04 | Senosiain S A De C V Lab | Composicion farmaceutica para el uso en el tratamiento de infecciones de transmision sexual. |
| KR20170052626A (ko) * | 2014-09-05 | 2017-05-12 | 심바이오믹스 세러퓨틱스 엘엘씨 | 세균질증 치료에 사용하기 위한 세크니다졸 |
| CA2988082C (en) | 2015-06-01 | 2020-09-29 | Symbiomix Therapeutics, Llc | Novel nitroimidazole formulations and uses thereof |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2581707B2 (ja) * | 1987-10-02 | 1997-02-12 | 科研製薬株式会社 | 抗真菌剤組成物 |
| US5536743A (en) * | 1988-01-15 | 1996-07-16 | Curatek Pharmaceuticals Limited Partnership | Intravaginal treatment of vaginal infections with buffered metronidazole compositions |
| SK282072B6 (sk) * | 1991-01-30 | 2001-10-08 | The Wellcome Foundation Limited | Tableta s obsahom lamotrigínu dispergovateľná vo vode a spôsob jej prípravy |
| GB9610359D0 (en) * | 1996-05-17 | 1996-07-24 | Edko Trading Representation | Pharmaceutical compositions |
| US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
| US6416779B1 (en) * | 1997-06-11 | 2002-07-09 | Umd, Inc. | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections |
| DE69831878D1 (de) * | 1997-11-24 | 2006-02-23 | Zhongming Zeng | Verwendung von dextrin, stärke oder glykogen zur behandlung von bakterieller vaginosis |
| US20030059471A1 (en) * | 1997-12-15 | 2003-03-27 | Compton Bruce Jon | Oral delivery formulation |
| FR2777783A1 (fr) * | 1998-04-24 | 1999-10-29 | Innothera Lab Sa | Association pharmaceutique d'imidazoles pour le traitement local des vulvo-vaginites infectieuses et des vaginoses |
| ATE527360T1 (de) * | 1998-12-08 | 2011-10-15 | Glaxosmithkline Biolog Sa | Neue verbindungen abgeleitet von neisseria meningitidis |
| US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
| DE10011081A1 (de) * | 2000-03-09 | 2001-09-13 | Aventis Pharma Gmbh | Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel |
| WO2001095723A1 (en) * | 2000-06-15 | 2001-12-20 | Ssl International Plc | Parasiticidal composition |
| US20030064103A1 (en) * | 2001-05-01 | 2003-04-03 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
| US20030017207A1 (en) * | 2001-05-01 | 2003-01-23 | Lin Shun Y. | Compositions and methods for treating vulvovaginitis and vaginosis |
| US20030130225A1 (en) * | 2001-10-16 | 2003-07-10 | Nawaz Ahmad | Novel methods of treating local fungal and bacterial infections |
| MXPA02007641A (es) | 2002-08-08 | 2004-04-02 | Alparis Sa De Cv | Uso de farmaceutico de la combinacion de fluconazol-tinidazol y su composicion para la administracion oral. |
| US20040033968A1 (en) * | 2002-08-16 | 2004-02-19 | Lin Shun Y. | Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections |
-
2004
- 2004-01-22 US US10/762,616 patent/US8309103B2/en not_active Expired - Fee Related
- 2004-12-17 JP JP2006550972A patent/JP2007518797A/ja active Pending
- 2004-12-17 ES ES04808700T patent/ES2280150T3/es not_active Expired - Lifetime
- 2004-12-17 DE DE602004021638T patent/DE602004021638D1/de not_active Expired - Fee Related
- 2004-12-17 BR BRPI0418065-8A patent/BRPI0418065A/pt not_active Application Discontinuation
- 2004-12-17 DE DE04808700T patent/DE04808700T1/de active Pending
- 2004-12-17 EP EP04808700A patent/EP1712229B1/en not_active Expired - Lifetime
- 2004-12-17 CA CA2553646A patent/CA2553646C/en not_active Expired - Fee Related
- 2004-12-17 WO PCT/MX2004/000094 patent/WO2005070421A1/es not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US8309103B2 (en) | 2012-11-13 |
| US20050165077A1 (en) | 2005-07-28 |
| BRPI0418065A (pt) | 2007-04-17 |
| ES2280150T1 (es) | 2007-09-16 |
| EP1712229A1 (en) | 2006-10-18 |
| WO2005070421A1 (es) | 2005-08-04 |
| DE04808700T1 (de) | 2007-08-09 |
| JP2007518797A (ja) | 2007-07-12 |
| CA2553646C (en) | 2012-01-31 |
| EP1712229B1 (en) | 2009-06-17 |
| CA2553646A1 (en) | 2005-08-04 |
| DE602004021638D1 (de) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5741525A (en) | Vaginal pharmaceutical hydrogen peroxide composition | |
| US20030017207A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
| KR102658716B1 (ko) | 피부 감염 및 점막 감염의 국소 치료를 위한 에멀젼 | |
| RU2366450C1 (ru) | Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций | |
| ES2532863T3 (es) | Uso de nifuratel para tratar infecciones provocadas por especies de Atopobium | |
| RU2327486C1 (ru) | Лекарственное средство для лечения инфекционно-воспалительных заболеваний, обладающее иммуномодулирующим, антивирусным, антибактериальным, антиоксидантным, мембраностабилизирующим, противовоспалительным, антитоксическим свойствами | |
| CN105342987A (zh) | 一种凝胶及其制备方法和应用 | |
| HU215443B (hu) | Többféle hatóanyagot tartalmazó gyógyszerkészítmények, főként hüvelykúp, baktericid, fungicid, protozoa- és vírusellenes kombinált hatással | |
| ES2280150T3 (es) | Asociacion de fluconazol-tinidazol para el tratamiento de infecciones vaginales, su composicion, proceso de preparacion y uso. | |
| ES2734280T3 (es) | Composición farmacéutica para su uso en el tratamiento de infecciones de transmisión sexual | |
| US20040033968A1 (en) | Optimal volume of intra-vaginal semisolid dosage forms for treating vaginal infections | |
| US20030064103A1 (en) | Compositions and methods for treating vulvovaginitis and vaginosis | |
| EP3658131B1 (en) | Composition for the treatment of bacterial vaginosis | |
| KR20080083190A (ko) | 외음질 표면에 생체접착을 위한 약물 전달 시스템 | |
| MXPA06008279A (en) | Fluconazole-tinidazole combination for the treatment of vaginal infections, composition thereof and preparation and use of same | |
| RU2320319C1 (ru) | Суппозитории вагинальные | |
| JP2000119186A (ja) | スクラルファート含有局所投与用医薬組成物 | |
| KR102784739B1 (ko) | 질 세정용 조성물 | |
| KR20250162796A (ko) | 보호용 생체반응성 중합체 씰 | |
| US20210401806A1 (en) | Compositions and methods for treatment of vaginal infections | |
| WO2024220677A1 (en) | Methods for treating and preventing microbial biofilms through the use of glycerol on microbes | |
| RU2498806C2 (ru) | Фармацевтический состав для лечения инфекционных воспалительных заболеваний в гинекологии и способ его получения | |
| EA041079B1 (ru) | Эмульсия для местного лечения инфекций кожи и слизистых оболочек | |
| AU2002309593A1 (en) | Composition comprising antifungal agents for treating vulvovaginitis and vaginosis |